Alzheimer’s drugs eyed as next big obesity-like opportunity
Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...
Abbvie to record $3.5 billion charge related to schizophrenia drug
Abbvie said on Friday it would record a charge of about $3.5 billion related to its experimental schizophrenia drug, ...
Alzheimer’s Drugs Eyed by Investors Seeking Obesity-Like Gains
Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...
China Medical System （00867）Obtained New Drug ZUNVEYL for the Treatment of Mild-to-Moderate Dementia of the Alzheimer’s Type
As the second oral therapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of Alzheimer’s disease during the past decade, ZUNVEYL demonstrates a potentially better safety ...
Could Alzheimer’s treatment drugs be the next big investor opportunity after obesity pills?
Alzheimer’s drugs could unlock a $13 billion market by 2030, with Biogen, Eli Lilly, Novo Nordisk, Roche, and UCB leading the ...
Alzheimer’s disease market expected to reach $19.3bn across the 8MM by 2033
While the Alzheimer’s market is projected to experience strong growth throughout the forecast period across the 8MM, unmet ...
Why Alzheimer’s Scientists Are Re-thinking the Amyloid Hypothesis
For decades, scientists have been trying to develop therapeutics for people living with Alzheimer’s disease, a progressive ...
Rolling Out6d
5 ways this cancer drug could revolutionize Alzheimer’s treatment
Groundbreaking research reveals how a cancer drug could restore brain function in early Alzheimer's patients by targeting glucose metabolism. Here's what you need to know.
BioSpace4dOpinion
Opinion: The Cocktail Recipe That Will Cure Alzheimer’s
Effectively treating and preventing this common form of dementia will require a cocktail of drugs and a combination of ...
China Medical System Secures Rights to Alzheimer’s Drug ZUNVEYL
Discover outperforming stocks and invest smarter with Top Smart Score StocksFilter, analyze, and streamline your ...
Alpha Cognition Inks $44 Million Licensing Pact For Its Alzheimer's Drug In China
Alpha Cognition and China Medical System sign a $44M licensing deal for Zunveyl. ALPHA-1062 preclinical data shows benefits ...
The Misconceptions About Anavex Life Sciences' Blarcamesine Phase 2b/3 Trial In Alzheimer's Disease
Anavex Life Sciences' Blarcamesine trial raises concerns over approval. Learn why AVXL stock is undervalued, reflecting the ...